Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
Brain Neoplasms
/ drug therapy
Breast Neoplasms
/ complications
Clinical Trials as Topic
Combined Modality Therapy
Disease Management
Female
Humans
Molecular Targeted Therapy
Protein Kinase Inhibitors
/ administration & dosage
Quinolines
/ administration & dosage
Receptor, ErbB-2
/ antagonists & inhibitors
Treatment Outcome
breast
metastasis
molecular oncology
novel therapy
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
pubmed:
15
2
2020
medline:
6
10
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
HER2-positive (HER2+) breast cancer has become an effectively treatable disease in the era of targeted therapies, and outcomes have improved such that prognosis of this subtype is demonstrated to be superior to HER2-negative disease. Despite these advances, durable responses in HER2+ metastatic disease are challenged by the increased risk for brain metastasis. Neratinib is an irreversible pan-HER kinase inhibitor that has emerged as an effective agent when combined with capecitabine for the management of HER2+ metastatic breast cancer patients with brain metastasis. The randomized, Phase III, NALA trial compares neratinib plus capecitabine to a currently prevailing regimen of lapatinib plus capecitabine and is provided herein. Analysis of NALA portends meaningful changes on the horizon for the management of HER2+ metastatic breast cancer.
Identifiants
pubmed: 32057254
doi: 10.2217/fon-2019-0719
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Quinolines
0
Receptor, ErbB-2
EC 2.7.10.1
neratinib
JJH94R3PWB
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM